Clinical Updates

The Food and Drug Administration approved a new once-a-day H.I.V. treatment from Gilead Sciences that contains four different drugs in… »   

The US Food and Drug Administration (FDA) approved the mTOR inhibitor everolimus (Afinitor) last week for use in postmenopausal women… »   

The first trial to study patients with acute coronary syndrome who do not undergo coronary stenting or bypass surgery found… »   

Pfizer Inc has settled a lawsuit accusing Impax Laboratories Inc of infringing patents covering the overactive bladder drug Detrol LA.

An internationally recognized melanoma researcher at Moffitt Cancer Center and colleagues at the University of Kiel in Germany, including Axel… »   

Pfizer Inc and Johnson & Johnson said they were scrapping further studies of one of the most anticipated experimental Alzheimer’s… »   

The finance chief of Bayer, Germany’s largest drugmaker, raised the prospect of a dividend increase next year, following a higher… »   

Genetic Technologies Ltd said its lead cancer test BrevaGen has been cleared for sale in California, which it expects to… »   

Novo Nordisk’s bid to challenge Sanofi’s dominance of the long-lasting insulin market hit another snag after U.S. regulators delayed approval… »   

Private equity firm TPG said on Monday it would acquire U.S.-based Par Pharmaceutical Cos Inc for $1.9 billion in the… »   

The U.S. Food and Drug Administration warned consumers on Friday against eating products of the Mexicali Cheese Corp because the… »   

Questcor Pharmaceuticals Inc reported strong second-quarter sales of its flagship multiple sclerosis drug, sending its shares up as much as… »   

Pfizer Inc, bowing to allegations of deceptive advertising lodged by a consumer watchdog group, has agreed to drop “breast health”… »   

It took Carl Icahn four years, a bitter proxy fight and litigation to make an estimated 22 percent return on… »   

Drug industry productivity is finally improving after years of research disappointment, as drugmakers shift their focus from mass markets to… »